SCOPUS 정보 검색 플랫폼

Diabetologia

Volumn 52, Issue 10, 2009, Pages 2234-2235

The longest ever randomised controlled trial of insulin glargine: Study design and HbA1c findings

(1) Currie, C J a

a CARDIFF UNIVERSITY (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC RETINOPATHY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; VISUAL IMPAIRMENT;

DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 69949179964 PISSN: 0012186X EISSN: 14320428 Source Type: Journal
DOI: 10.1007/s00125-009-1477-6 Document Type: Letter

Times cited : (11)

References (5)

1
- 68449099924
- Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: A long-term, randomised, open-label study
- 10.1007/s00125-009-1415-7
- J Rosenstock V Fonseca JB [tmp] McGill, et al. 2009 Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study Diabetologia 10.1007/s00125-009-1415-7
- (2009) Diabetologia
- Rosenstock, J.¹ Fonseca, V.² McGill, J.B.³

2
- 68449088653
- Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study
- 10.1007/s00125-009-1452-2
- J Rosenstock V Fonseca JB [tmp] McGill, et al. 2009 Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study Diabetologia 10.1007/s00125-009-1452-2
- (2009) Diabetologia
- Rosenstock, J.¹ Fonseca, V.² McGill, J.B.³

3
- 68449094325
- The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
- 10.1007/s00125-009-1440-6
- CJ Currie CD Poole EAM Gale 2009 The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 10.1007/s00125-009- 1440-6
- (2009) Diabetologia
- Currie, C.J.¹ Poole, C.D.² Gale, E.A.M.³

4
- 33947386544
- The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis
- CD Poole T Tetlow P [tmp] McEwan P Holmes CJ Currie 2007 The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis Curr Med Res Opin 23 Suppl. 1 S41 S48
- (2007) Curr Med Res Opin , vol.23 , Issue.SUPPL. 1
- Poole, C.D.¹ Tetlow, T.² McEwan, P.³ Holmes, P.⁴ Currie, C.J.⁵

5
- 68449088664
- Does diabetes therapy influence the risk of cancer?
- 10.1007/s00125-009-1441-5
- U Smith EAM Gale 2009 Does diabetes therapy influence the risk of cancer? Diabetologia 10.1007/s00125-009-1441-5
- (2009) Diabetologia
- Smith, U.¹ Gale, E.A.M.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.